Highlights
February 4, 2010
Repligen Reports Third Quarter Fiscal Year 2010 Financial Results more >
February 3, 2010
Repligen Receives Notice of Allowance for Recombinant Protein A Patent more >
February 1, 2010
Repligen to Present at the BIO CEO & Investor Conference
Monday, February 8th, 2:00 p.m. EST more >
January 29, 2010
Repligen Announces Conference Call of Third Quarter Fiscal Year 2010 Results
Thursday, February 4th, 10:00 a.m. EST more >
January 28, 2010
Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A more >
December 15, 2009
Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program more >
December 9, 2009
Repligen Reports Phase 3 Clinical Trial Results of
RG1068 in Pancreatic Imaging more >
November 5, 2009
Repligen Reports Second Quarter Fiscal Year 2010 Financial Results more >
October 22, 2009
Repligen Licenses Potential Treatment for Spinal Muscular Atrophy
Conference Call Scheduled for Friday, October 23 at 8:30 EDT more >
October 22, 2009
Spinal Muscular Atrophy Program References more >
September 25, 2009
Repligen Announces Identification of Drug Target for Friedreich's Ataxia
Study Published in the September 25, 2009 Issue of Chemistry & Biology
more >
Events
Q3 Fiscal Year 2010 Earnings Conference Call
Thursday, February 4th, 2010 at 10:00 A.M. EST
Dial-in: (800) 510-9836
International: (617) 614-3670
Passcode: 51466310
Listen to Webcast
BIO CEO and Investor Conference
Monday, February 8th, 2010 at 2:00 P.M. EST
Listen to Webcast